Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET)

Kulke MH, Frauenhoffer CS, Hooshmand SM, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Hornick J, Fuchs CS, Redston MS. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). Proc Am Soc Clin Oncol. 2007.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.